A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab
The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total patho...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/29/6/337 |
| _version_ | 1827660989123788800 |
|---|---|
| author | Charlie Yang Raida Khwaja Patricia Tang Nancy Nixon Karen King Sasha Lupichuk |
| author_facet | Charlie Yang Raida Khwaja Patricia Tang Nancy Nixon Karen King Sasha Lupichuk |
| author_sort | Charlie Yang |
| collection | DOAJ |
| description | The reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total pathological complete response (tpCR) rates (lack of residual invasive cancer in resected breast tissue and axillary nodes), of MYL-1401O to reference trastuzumab (TRZ) in the neoadjuvant setting for HER2+ early breast cancer (EBC) in Alberta, Canada. Neoadjuvant patients with HER2+ EBC treated with TRZ from November 2018–October 2019 and MYL-1401O from December 2019–September 2020 were identified. Logistic regression was used to control for variables potentially associated with tpCR: trastuzumab product, age, pre-operative T- and N-stage, grade, hormone receptor (HR)-status, HER2-status, chemotherapy regimen, and chemotherapy completion. tpCR was 35.6% in the MYL-1401O group (<i>n</i> = 59) and 40.3% in the TRZ (<i>n</i> = 77) group, <i>p</i> = 0.598. After controlling for clinically relevant variables, there was no significant difference in the odds of achieving tpCR in patients treated with TRZ versus MYL-1401O (OR 1.1, 95% CI 0.5–2.4, <i>p</i> = 0.850). tpCR rates were similar for patients treated with MYL-1401O compared to trastuzumab in our real world study of HER2+ neoadjuvant EBC and comparable to pivotal phase 3 trials. |
| first_indexed | 2024-03-10T00:02:14Z |
| format | Article |
| id | doaj.art-54fb96f00a8f465ca1356ccb18df6fe3 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T00:02:14Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-54fb96f00a8f465ca1356ccb18df6fe32023-11-23T16:14:11ZengMDPI AGCurrent Oncology1198-00521718-77292022-06-012964224423410.3390/curroncol29060337A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference TrastuzumabCharlie Yang0Raida Khwaja1Patricia Tang2Nancy Nixon3Karen King4Sasha Lupichuk5Department of Oncology, Tom Baker Cancer Centre, Calgary, AB T2N4N2, CanadaDepartment of Oncology, Cross Cancer Institute, Edmonton, AB T6G1Z2, CanadaDepartment of Oncology, Tom Baker Cancer Centre, Calgary, AB T2N4N2, CanadaDepartment of Oncology, Tom Baker Cancer Centre, Calgary, AB T2N4N2, CanadaDepartment of Oncology, Cross Cancer Institute, Edmonton, AB T6G1Z2, CanadaDepartment of Oncology, Tom Baker Cancer Centre, Calgary, AB T2N4N2, CanadaThe reduced cost of trastuzumab biosimilars has led to increased adoption for HER2-positive breast cancer. This review of trastuzumab biosimilars encompasses this development and real world clinical data in early breast cancer. In addition, we present a retrospective study evaluating the total pathological complete response (tpCR) rates (lack of residual invasive cancer in resected breast tissue and axillary nodes), of MYL-1401O to reference trastuzumab (TRZ) in the neoadjuvant setting for HER2+ early breast cancer (EBC) in Alberta, Canada. Neoadjuvant patients with HER2+ EBC treated with TRZ from November 2018–October 2019 and MYL-1401O from December 2019–September 2020 were identified. Logistic regression was used to control for variables potentially associated with tpCR: trastuzumab product, age, pre-operative T- and N-stage, grade, hormone receptor (HR)-status, HER2-status, chemotherapy regimen, and chemotherapy completion. tpCR was 35.6% in the MYL-1401O group (<i>n</i> = 59) and 40.3% in the TRZ (<i>n</i> = 77) group, <i>p</i> = 0.598. After controlling for clinically relevant variables, there was no significant difference in the odds of achieving tpCR in patients treated with TRZ versus MYL-1401O (OR 1.1, 95% CI 0.5–2.4, <i>p</i> = 0.850). tpCR rates were similar for patients treated with MYL-1401O compared to trastuzumab in our real world study of HER2+ neoadjuvant EBC and comparable to pivotal phase 3 trials.https://www.mdpi.com/1718-7729/29/6/337trastuzumabbiosimilarMYL-1401OHER2+breast cancerearly stage |
| spellingShingle | Charlie Yang Raida Khwaja Patricia Tang Nancy Nixon Karen King Sasha Lupichuk A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab Current Oncology trastuzumab biosimilar MYL-1401O HER2+ breast cancer early stage |
| title | A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab |
| title_full | A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab |
| title_fullStr | A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab |
| title_full_unstemmed | A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab |
| title_short | A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-1401O versus Reference Trastuzumab |
| title_sort | review of trastuzumab biosimilars in early breast cancer and real world outcomes of neoadjuvant myl 1401o versus reference trastuzumab |
| topic | trastuzumab biosimilar MYL-1401O HER2+ breast cancer early stage |
| url | https://www.mdpi.com/1718-7729/29/6/337 |
| work_keys_str_mv | AT charlieyang areviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT raidakhwaja areviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT patriciatang areviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT nancynixon areviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT karenking areviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT sashalupichuk areviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT charlieyang reviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT raidakhwaja reviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT patriciatang reviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT nancynixon reviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT karenking reviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab AT sashalupichuk reviewoftrastuzumabbiosimilarsinearlybreastcancerandrealworldoutcomesofneoadjuvantmyl1401oversusreferencetrastuzumab |